Abstract

Antipsychotic drugs are licensed as treatment for schizophrenia and other mental health disorders but can cause a range of unwanted effects that require close monitoring by, and close collaboration between, healthcare professionals across a range of settings. This applies to both first-generation and second-generation antipsychotics (FGAs and SGAs; sometimes known as conventional and atypical antipsychotics, respectively). Here we discuss monitoring for unwanted effects of antipsychotics in adults, with a particular focus on SGAs.